Article Details

Why Pfizer Will Profit From Merck's Rival Pneumococcal Vaccine | The Motley Fool

Retrieved on: 2021-10-09 15:11:15

Tags for this article:

Click the tags to see associated articles and topics

Why Pfizer Will Profit From Merck's Rival Pneumococcal Vaccine | The Motley Fool. View article details on hiswai:

Excerpt

Key Points · Pfizer and Merck recently settled a lawsuit related to Pfizer's patents for pneumococcal vaccines. · Pfizer will receive 7.25% royalties on Merck's ...

Article found on: www.fool.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up